Loading clinical trials...

AGN-151586 Dose-Ranging Study for Treatment of Glabellar Lines | Clinical Trials | Clareo Health

COMPLETEDPHASE2

AGN-151586 Dose-Ranging Study for Treatment of Glabellar Lines

A Phase 2b Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of AGN-151586 in Participants With Moderate to Severe Glabellar Lines

NCT04096326•Allergan

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate the safety and efficacy of AGN-151586 over a range of doses for the treatment of moderate to severe glabellar lines (GL).

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Female participants willing to minimize the risk of inducing pregnancy for the duration of the clinical study and follow-up period (at least 10 weeks after study intervention).

Exclusion Criteria

•Known immunization or hypersensitivity to any botulinum neurotoxin serotype
•Any medical condition that may put the participant at increased risk with exposure to AGN-151586, including diagnosed myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, or any other condition that might interfere with neuromuscular function
•Marked facial asymmetry, dermatochalasis, deep dermal scarring, excessively thick sebaceous skin, or the inability to substantially lessen facial lines even by physically spreading them apart, as determined by the investigator
•Any brow or eyelid ptosis, as determined by the investigator
•Infection or skin disorder at the injection sites
•History of facial nerve palsy
•Any uncontrolled systemic disease
•Anticipated need for treatment with botulinum neurotoxin of any serotype for any reason during the study (other than study intervention)
•Anticipated need for surgery or overnight hospitalization during the study
•Prior periorbital surgery, facial lift (full face or mid-face), thread lift, brow lift, or related procedures (eg, eyelid \[blepharoplasty\] and/or eyebrow surgery)
+2 more criteria

Locations (9)

Center for Dermatology Clinical Research /ID# 237798

Fremont, California, United States

Ava T. Shamban MD - Santa Monica. /ID# 235353

Santa Monica, California, United States

Skin and Cancer Associates, LLP /ID# 236231

Miami, Florida, United States

Laser and Skin Surgery Center of Indiana /ID# 236588

Indianapolis, Indiana, United States

Wilmington Dermatology Center /ID# 237055

Wilmington, North Carolina, United States

Kgl, Llc /Id# 234798

Newtown Square, Pennsylvania, United States

DermResearch Inc. /ID# 234483

Austin, Texas, United States

Austin Institute for Clinical Research at SBA Dermatology /ID# 236646

Houston, Texas, United States

Austin Institute for Clinical Research /ID# 237135

Pflugerville, Texas, United States

Key Dates

Start Date

September 26, 2019

Primary Completion Date

September 9, 2020

Completion Date

September 9, 2020

Last Updated

July 28, 2023

Enrollment

198

ACTUAL participants

Conditions

Glabellar Lines

Interventions

AGN-151586

DRUG

Placebo

DRUG

A Study to Investigate the Safety and Efficacy of YY003 in Adults with Moderate to Severe Glabellar Lines

NCT06481475

Moderate to Severe Glabellar Lines

View study

ACTIVE_NOT_RECRUITINGPHASE2

A Study to Evaluate AI-09 In Participants With Glabellar Lines

NCT07321834

Glabellar Lines

View study

ACTIVE_NOT_RECRUITINGPHASE3

A Study on the Efficacy and Safety of Repeated Treatments With Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 28, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

AGN-151586 Dose-Ranging Study for Treatment of Glabellar Lines

Inclusion Criteria

Exclusion Criteria

A Study to Investigate the Safety and Efficacy of YY003 in Adults with Moderate to Severe Glabellar Lines

A Study to Evaluate AI-09 In Participants With Glabellar Lines

A Study on the Efficacy and Safety of Repeated Treatments With Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines

Clinical Trial to Evaluate the Safety and Efficacy of JTM201 to Treat Moderate or Severe Glabellar Lines

Non-interventional Study, Long Term Treatment on Glabellar Lines With Dysport® in Subjects of Chinese Origin

Study of AGN-151586 in Japanese Participants With Moderate to Severe Glabellar Lines